Givinostat hydrochloride

Research use only, not for human use.

Givinostat hydrochloride is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.

Givinostat hydrochloride is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.(In Vitro):Givinostat hydrochloride inhibits JS-1 cell proliferation in a concentration-dependent manner. Givinostat hydrochloride (≥500 nM) is associated with significant inhibition of JS-1 cell proliferation. Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat hydrochloride ≥250 nM plus LPS and the group without LPS treatment. Givinostat hydrochloride (25, 50, and 100 nM) reduces IL-1β secretion more than 70%. Givinostat hydrochloride suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM, but at 100 and 200 nM, there is no reduction.(In Vivo):Givinostat hydrochloride (10 mg/kg) reduces serum TNFα by 60%. Pretreatment of Givinostat hydrochloride (0.1 mg/kg) significantly reduces the circulating TNFα by nearly 90%.

Givinostat HCl; ITF2357; ITF-2357; ITF 2357; ITF2357 HCl; ITF2357 hydrochloride

Cell Cycle/DNA Damage

HDAC

——

——

——

199657-29-9

458.0

C24H28ClN3O4

>98% (HPLC)

——

Cl.CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1

——

(-20℃)

With Ice Pack

≥ 2 years